These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35873553)

  • 1. Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer.
    Hu Y; Ren S; Wang R; Han W; Xiao P; Wang L; Yu F; Liu W
    Front Pharmacol; 2022; 13():816683. PubMed ID: 35873553
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial.
    Leonetti A; Minari R; Boni L; Gnetti L; Verzè M; Ventura L; Musini L; Tognetto M; Tiseo M
    Clin Lung Cancer; 2021 Sep; 22(5):473-477. PubMed ID: 33762169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports.
    Shi L; Gao S; Tong L; Meng Q; Zhou S; Yu D; Dong Y; Liu Z
    Front Oncol; 2023; 13():1120511. PubMed ID: 37409244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological complete response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinase positive non-small cell lung cancer: A case report.
    Wang LM; Zhao P; Sun XQ; Yan F; Guo Q
    World J Clin Cases; 2023 Aug; 11(22):5322-5328. PubMed ID: 37621597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Left total pneumonectomy performed after alectinib treatment for anaplastic lymphoma kinase-positive lung adenocarcinoma: a case report.
    Wang Z; Shi Y; Zhang P; Chen Y
    Chin Clin Oncol; 2023 Dec; 12(6):70. PubMed ID: 38195077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review.
    Gu R; Shi Z; Duan T; Song M
    Onco Targets Ther; 2021; 14():5107-5113. PubMed ID: 34707369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative alectinib in a patient with locally advanced anaplastic lymphoma kinase positive non-small cell lung cancer (NSCLC): a case report.
    Yue P; Zhang S; Zhou L; Xiang J; Zhao S; Chen X; Dong L; Yang W; Xiang Y
    Transl Cancer Res; 2021 Aug; 10(8):3856-3863. PubMed ID: 35116684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy.
    Cao P; Zhao Q; Li Y; Shi R; Zhu G; Zhang Z; Zhang H; Liu M; Wei S; Liu H; Chen J
    Front Pharmacol; 2023; 14():1140894. PubMed ID: 37663243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alectinib: A Review in Advanced, ALK-Positive NSCLC.
    Paik J; Dhillon S
    Drugs; 2018 Aug; 78(12):1247-1257. PubMed ID: 30030733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy and safety of crizotinib and alectinib in ALK-positive non-small cell lung cancer treatment and predictive value of CEA and CA125 for treatment efficacy.
    Li Z; Zhao J
    Am J Transl Res; 2021; 13(11):13108-13116. PubMed ID: 34956530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
    Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
    N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
    Shaw AT; Gandhi L; Gadgeel S; Riely GJ; Cetnar J; West H; Camidge DR; Socinski MA; Chiappori A; Mekhail T; Chao BH; Borghaei H; Gold KA; Zeaiter A; Bordogna W; Balas B; Puig O; Henschel V; Ou SI;
    Lancet Oncol; 2016 Feb; 17(2):234-242. PubMed ID: 26708155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
    Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
    J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis.
    Yang YL; Xiang ZJ; Yang JH; Wang WJ; Xiang RL
    Ann Palliat Med; 2020 Jul; 9(4):1782-1796. PubMed ID: 32527124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement.
    Zhang C; Li SL; Nie Q; Dong S; Shao Y; Yang XN; Wu YL; Yang Y; Zhong WZ
    J Thorac Oncol; 2019 Apr; 14(4):726-731. PubMed ID: 30408570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.
    McKeage K
    Drugs; 2015 Jan; 75(1):75-82. PubMed ID: 25428710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transformation of
    Xia G; Huang J; Ni J; Song M; Zhang J; Hofman P; Christopoulos P; Grenda A; Huang M
    Transl Lung Cancer Res; 2023 Mar; 12(3):637-646. PubMed ID: 37057117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
    Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
    J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.
    Lin JJ; Zhu VW; Schoenfeld AJ; Yeap BY; Saxena A; Ferris LA; Dagogo-Jack I; Farago AF; Taber A; Traynor A; Menon S; Gainor JF; Lennerz JK; Plodkowski AJ; Digumarthy SR; Ou SI; Shaw AT; Riely GJ
    J Thorac Oncol; 2018 Oct; 13(10):1530-1538. PubMed ID: 29935304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.